RxDoctor Payments Data

Andrew Hersh, MD

Pulmonary Disease · Montrose, CONPI 1285924480

Payments from drug & device makers

$4,722in general payments, 2019–2025

Across 48 payments — averaging $98.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$2K
  • Noah Medical Corporation$1K
  • Medtronic$761
  • GSK$155
  • Johnson & Johnson$151
  • Sanofi-aventis U.S. LLC$100
  • plus $314 from 10 others

What the payments were for

  • Travel & lodging$2,89461%
  • Food & beverage$1,72837%
  • Education$1002%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,722 in reported general payments places this provider in the 65th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$86,843
Medicare patients
312
Services billed
1,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab18$67,366
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$48,860
Stiolto RespimatTiotropium Br/Olodaterol Hcl56$41,782
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$14,750
Spiriva RespimatTiotropium Bromide12$12,550
Varenicline Tartrate51$10,778
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$8,584
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$7,025
SymbicortBudesonide/Formoterol Fumarate23$6,222
Breo ElliptaFluticasone/Vilanterol11$4,241
Albuterol Sulfate HfaAlbuterol Sulfate32$1,200
Gabapentin35$628
Prednisone55$245
Azithromycin16$222
Montelukast Sodium12$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta$155$129,052100 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$33$54,33268 claims
AstraZenecaBreztri Aerosphere, Symbicort$72$20,97346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Montrose

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →